Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17435)	3/14/1998 3:04:00 PM
From: Biotech Jim	Read Replies (3) \| Respond to of 32384

I had realized that the SRC work was done by Joan as a postdoc, and that launched her into the SUNY faculty position. I was just checking to see who was in the know. I should have realized that you would set the record straight, Henry! Congrats. On another front, let's get a discussion going about the leaders of LGND's science and the current/future focus on the preclinical front. Who are the bright stars, and where did they come from? How good is their combinatorial chem and small molecule program? Is the future focused more on cytokine receptors than ligand-activated steroid hormone transcription factors? If LGND is to take some programs to the clinic themselves, who will lead the development efforts and what is their experience in this arena? I would like to have this thread transcend the personal attacks and bickering, and deal with some scientific and clinical development issues. If that happens, then maybe we can attract more individuals with such expertise and heighten the fundamental analysis. Biotech Jim